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The identification of tumor-specific antigens has been an elusive goal in human
tumor immunology. Antibodies present in the sera of some cancer patients that react
with autologous cultured tumorcells have provided reagents for the initial detection
of restricted tumor cell surface antigens (reviewed in reference 1). We termed this
approach "autologous typing." The antigens detected by this method that are restricted
to the autologous tumor were designated "class 1" or "unique" tumor antigens. Of
the six class 1 melanoma antigens that have been detected using this approach how-
ever, only one (FD) has been amenable to biochemical analysis (2). In previous studies
we demonstrated that the FD specificity in the autologous cell line SK-MEL-131
is carried on a glycoprotein of -90 kD (gp90). We have also produced mouse poly-
clonal (3) and monoclonal (4) antibodies to this glycoprotein . These mouse mAbs
detected gp90 in a large variety of cultured human cells and in some normal tissues,
showing that the FD specificity (recognized by the patient's serum) is a unique de-
terminant carried on a common molecule (detected by mouse antibodies) . We now
show that this common molecule, gp90, is a previously recognized glycoprotein that
was originally identified as a melanoma antigen using mouse mAbs and designated
gp95 (5) or p97 (6, 7).
Materials and Methods
Cell Lines andAntibodies.
￿
Melanoma cell linesSK-MEL-28 (FD epitope negative) and SK-
MEL-131, clone 1 .36 (FD epitope positive), have been described (2), as have the conditions
for their culture (2). Mouse mAbs 112 and KF23 have also been described previously (4,
5). Human serum from patient FD detects a unique epitope on SK-MEL-131 cells (2).
Radioimmunoprecipilation and PACE.
￿
Methods for the immunoprecipitation of 12'I-labeled
antigens, as well as sequential immunoprecipitation procedures, are described in references
2 and 3 . SDS-PAGE and IEF were described previously (3, 8).
Purification ofgp90 and Determination of its NH2-terminal Amino Acid Sequence.
￿
SK-MEL-28
melanoma cells were cultured in Eagle's MEM containing insulin-transferrin-selenium (Col-
laborative Research, Lexington, MA) for 3 d. The spent medium (5 liters) was concentrated
10-fold and proteins were precipitated with 50% saturated ammonium sulfate. The precipi-
tate was dissolved in PBS, dialyzed against the same buffer, and applied to a con A-Sepharose
column (10 ml; Pharmacia Fine Chemicals, Piscataway, NJ). Unbound proteins were removed
by washing with PBS and bound glycoproteins were eluted with 1.0 M methyl a-D-mannoside
in PBS (compare reference 3). After dialyzing the eluate against 0.1 M NaCl, 0.01 M Tris-
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HCI, pH 7 .0, the sample was passed through a column of normal mouse Ig (prepared from
Tresyl-Sepharose; Pharmacia Fine Chemicals). The unbound sample was then applied to
a column of mAb KF23-Sepharose (3.5 mg/ml), also prepared from Tresyl-Sepharose. The
column was washed with 0.1 M NaCl, 0.01 M Tris-HCI, pH 7.0, and 0.5 M NaCl, 0 .01 M
Tris, pH 8.5, and antigen was then eluted with 0.1 M NaCl, 50 mM diethylamine-HCI (pH
11.5). For further purification, the column eluate was dialyzed against water, lyophilized, and
separated by SDS-PAGE on a 7% gel. After electrophoresis, the antigen (N10 gg) was trans-
ferred to polyvinylidene difluoride membrane (Millipore Continental Water Systems, Bed-
ford, MA) in transfer buffer (10 mM 3-[cyclohexylamino]-1-propanesulfonic acid containing
10% methanol) as described by Matsudaira (9). The membrane was rinsed in water and air
dried and the 90-95-kD region was located using prestained standards in adjacent lanes and
cut out. The sample was used for amino acid sequencing using a gas phase sequenator(Ap-
plied Biosystems, Inc., Foster City,CA) at the Harvard Microchemistry facility (Boston, MA).
Tryptic Peptide Mapping.
￿
Proteins, isolated by antibody affinity chromatography and SDS-
PAGE as described above, were radioiodinated with "'I by the chloramine T procedure (10)
and further purified by SDS-PAGE. Gel slices containing the antigen were washed succes-
sively with 10% acetic acid and 10% methanol. After drying by lyophilization they were placed
in a solution of 50 ug/ml of DPCC-trypsin (Sigma Chemical Co., St. Louis, MO) in 0.13
M ammonium bicarbonate. After incubating overnight at 37°C, the trypsin solution was
removed, the slices were washed with water, and the combined extracts were lyophilized. The
tryptic digests were analyzed by two-dimensional (2D) mapping as described by Elder et al.
(I1) and the peptides were detected by autoradiography with XAR-5 film (Kodak).
Results
Two linesofevidence demonstrated the relationship between the FD epitope-bearing
gp90 and gp95/p97. Sequential radioimmunoprecipitation experiments showed that
preclearing of a 125I-labeled antigen preparation from the allogeneic melanoma cell
line SK-MEL-28 with mAb KF23 (detecting gp90) removed antigen reacting with
mAb 112 (detecting gp95) (Fig. 1). Also, mAb 112 removed all the antigen from SK-
MEL-131 reacting with human serum FD (detecting the unique epitope) . Further-
more, we determined the partial NH2-terminal amino acid sequence of purified
gp90 glycoprotein from SK-MEL-28 cells. The antigen was isolated from the spent
culture medium of SK-MEL-28 cells by con A-agarose and mAb KF23 antibody
affinity chromatography, followed by preparative SDS-PAGE. Afterthe affinity chro-
matography step, the sample contained three components in the 90-kD region (data
not shown), which were reduced to one component in 2D IEF SDS-PAGE after neur-
aminidase treatment (Fig. 2 A). Immunoprecipitation with mAb KF23 confirmed
that this component was gp90. Determination of the partial NH2-terminal amino
acid sequence by a gas phase sequenator showed identity to the previously reported
sequence for p97 derived either from NH2-terminal amino acid sequencing (12) or
deduced from the nucleotide sequence of the cloned gene (13) (Fig. 2 B). From these
data we conclude that gp90 is identical to the previously described gp95 and p97
antigens; in addition, the FD epitope is carried on the gp95/p97 glycoprotein. This
molecule has amino acid sequence homology to transferrin and also binds iron and
has been termed melanotransferrin (12) .
In an attempt to determine the biochemical basis for the expression of the FD
determinant in gp95/p97 from SK-MEL-131 cells, but not SK-MEL-28 cells, tryptic
peptide maps of the purified antigens from the two cell lines were compared (Fig.
3). No reproducible differences were found between the tryptic peptides of the an-
tigen from FD' and FD- cells.FURUKAWA ET AL .
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FIGURE 1 .
￿
Direct andsequen-
tial radioimmunoprecipitation
(RIPS) experiments comparing
antigens reactive with mAbs
KF23 (anti-gp90), 112 (anti-
gp95), andFD serum. (Leftpan-
es Direct immunoprecipitation
of 1251-labeled antigen from
SK-MEL-28 with mAb 112,
(lane I), mAb KF23, (lane 2),
and control mAb(lane 3) . (Right
paneo Sequential immunopre-
cipitation experiments . 1251-la-
beled antigen from SK-MEL-
28 (lanes 4-7) was precleared
four times with the first mAb
and protein A-agarose (Repli-
gen, Boston,MA) . The remain-
ing sample was reacted with the
second antibody and protein
A-agarose and theimmune pre-
cipitates were analyzed by SDS-
PAGE .The antigen preparation
was precleared withmAb KF23
(lanes 4 and 5) or control anti-
body (lanes 6 and 7) and was
subsequently immunoprecipi-
tated withmAb 112 (lanes 4and
6) or control antibody (lanes 5
and 7). The results indicate that
preclearing withmAbKF23 re-
moves antigen reacting with
mAb 112 . Preclearing SK-
MEL-131 (clone 1.36 ; reference
2) antigen with mAb 112 (lane
8) and controlmAb (lane 9) and
subsequent immunoprecipita-
tion withFD serum (lanes 8and
9) showed that the FD deter-
minant is carriedon gp95 .The
unidentified components in
some ofthe lanes are nonspecific
components .
FIGURE 2 . Purification and
partial amino acid sequence of
gp90 . (A)The two-dimensional
IEFSDS-PAGE analysis ofthe
sample purified as described in
Materials and Methods . The
sample was treated with neur-
aminidase (0 .3 U/ml for3 h at
37°C) before separation . Gp90
is indicated with an arrow ; the
other components are albumin,
which was later removed by pre-
parative SDS-PAGE, and IEF
markers(m) . (B) theNterminal
amino acid data on the purified
protein and the sequence is
compared with the published se-
quence for p97 (12, 13) .588
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FIGURE 3 .
￿
Comparison of tyrosine-containing tryptic
peptides of gp95/p97 from SK-MEL-28 (A) and SK-
MEL-131 (B) cells. Thepatterns are essentially identical ;
theminordifferences observed in thetwo patterns were
not reproducible .
Discussion
Although gp95/p97 is preferentially expressed on melanoma cell lines, it is found
on a range of other cultured cell types (5-7) . In vivo gp95/p97 is expressed strongly
in the majority ofmelanoma tumors but only weakly on epithelial cancers (14, 15) .
The expression of gp95/p97 on normal tissues is generally limited to sweat gland
ducts and the linings of blood vessels in some tissues (4) . Using double-determinant
assays, Brown et al . (16) demonstrated a range of0.1-610 ng/mg tissue in melanoma
tissues and a range of 0 .1-10 ng/mg in normal adult tissues .
The fact that the FD specificity is heat labile and trypsin sensitive suggests that
FD is a protein epitope . Both the original gp95/p97 from SK-MEL-131 and SK-
MEL-28 cells and neuraminidase-, endo-N-acetylglucosaminidase-, or N-glycanase-
treated products had identical molecular sizes as determined by SDS-PAGE (data
not shown), indicating that there are no major molecular differences, which would
have resulted in differences in mobility, in either the polypeptide or carbohydrate
moieties of gp95/p97 from FD' and FD- cell sources . No significant differences
were detected in 2D maps of 1251-labeled tryptic peptides of gp95/p97 from SK-
MEL-131 and -28 cells . These results suggest that discrete differences, such as single
amino acid substitutions, distinguish the two species . The observation made previ-FURUKAWA ET AL .
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ously (4) that FD serum only partially removes molecules reacting with KF26 (an-
other mAb detecting gp95/p97) could be explained by the low affinity of FD anti-
bodies, but it also raises the interesting possibility that a mixed population ofgp95/p97
molecules, corresponding to common and unique forms, may be produced by
SK-MEL-131 .
This demonstration that the autoimmunogenic melanoma epitope FD resides on
a common melanoma antigen (gp95/p97) raises a number of interesting questions
for tumor immunology. As only a single melanoma cell line in the series tested ex-
pressed the FD determinant, the expression of this novel epitope in gp95/p97 is un-
common . However, it focuses attention on the possibility of other changes in gp95/p97
in melanoma, and the available molecular probes for this glycoprotein (13) will permit
analyses of these modifications and their frequency. In contrast to the modification
resulting in the FD epitope, other possible transformation-related alterations in
gp95/p97 may not elicit humoral immunity. The possibility that such changes in
gp95/p97 could be targets for cellular immune responses against melanoma needs
to be examined .
Summary
Analysis of antibodies present in the serum of melanoma patient FD has shown
that they detect a unique tumor epitope present only on the autologous melanoma
cell line SK-MEL-131 . Previous results had shown that the unique FD epitope is
carried on a common glycoprotein of -90 kD, widely expressed on melanoma and
a few other cell types . We now show by sequential radioimmunoprecipitation and
partial amino acid sequencing that this common molecule is a previously recog-
nized melanoma antigen, originally identified by mouse mAbs, designated gp95 or
p97 (and also known as melanotransferrin) . Thus, FD is the first ofthe class I (unique)
melanoma antigens that has been characterized and related to a known cell surface
molecule .
Receivedfor publication 12 September 1988 and in revisedform 1 November 1988.
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